儿童多发性硬化9年残疾的早期预测因素
该研究纳入123例儿童多发性硬化患者,在起病时及1年、2年时进行临床和MRI评估,并随访9年。结果发现,基线视神经病变预测首次复发和9年残疾恶化,而高效治疗暴露降低复发风险;2年内新增≥2个T2病灶和EDSS变化预测9年残疾进展。
要点
- 基线视神经病变与9年残疾恶化相关(OR=6.45)。
- 高效治疗暴露降低首次复发风险(HR=0.31)。
- 2年内新增≥2个T2病灶预测9年残疾恶化(OR=4.91)。
核心结论
- 完整的基线MRI评估及病初2年准确的临床和MRI监测有助于预测儿童多发性硬化9年预后。
研究设计与样本
- 对123例儿童多发性硬化患者在起病时及1年、2年时进行临床和MRI评估,并完成9年临床随访。
主要发现
- 首次复发时间由视神经病变(HR=2.10,p=0.02)和高效治疗暴露(HR=0.31,p=0.005)预测。
- 9年残疾恶化的基线预测因素为视神经病变(OR=6.45,p=0.01)。
- 9年残疾恶化的1年预测因素包括EDSS变化(OR=26.05,p<0.001),2年预测因素包括EDSS变化(OR=16.38,p=0.02)和2年内≥2个新T2病灶(OR=4.91,p=0.02)。
- 9年EDSS评分更高的基线预测因素包括EDSS评分(β=0.58,p<0.001)、脑干病变(β=0.31,p=0.04)和颈髓病变数量(β=0.22,p=0.05)。
- 9年EDSS评分更高的1年预测因素包括EDSS变化(β=0.79,p<0.001)和≥2个新T2病灶(β=0.28,p=0.03),2年预测因素包括EDSS变化(β=0.55,p<0.001)和≥2个新T2病灶(β=0.35,p=0.01)。
关键数值与推荐
- 基线视神经病变预测首次复发(HR=2.10,p=0.02)和9年残疾恶化(OR=6.45,p=0.01)。
- 高效治疗暴露预测首次复发时间(HR=0.31,p=0.005)。
- 2年内≥2个新T2病灶预测9年残疾恶化(OR=4.91,p=0.02)和更高EDSS评分(β=0.35,p=0.01)。
临床怎么用
- 对儿童多发性硬化患者应进行完整的基线MRI评估,并在病初2年定期临床和MRI监测以识别残疾进展高风险者。
局限性
- 样本量有限(123例),可能影响结果外推。
- 观察性设计不能确立因果关系。
- 未报告多变量模型的具体校正变量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The purpose of this study was to assess early predictors of 9-year disability in pediatric patients with multiple sclerosis. METHODS: Clinical and magnetic resonance imaging (MRI) assessments of 123 pediatric patients with multiple sclerosis were obtained at disease onset and after 1 and 2 years. A 9-year clinical follow-up was also performed. Cox proportional hazard and multivariable regression models were used to assess independent predictors of time to first relapse and 9-year outcomes. RESULTS: Time to first relapse was predicted by optic nerve lesions (hazard ratio [HR] = 2.10, p = 0.02) and high-efficacy treatment exposure (HR = 0.31, p = 0.005). Predictors of annualized relapse rate were: at baseline, presence of cerebellar (β = -0.15, p < 0.001), cervical cord lesions (β = 0.16, p = 0.003), and high-efficacy treatment exposure (β = -0.14, p = 0.01); considering also 1-year variables, number of relapses (β = 0.14, p = 0.002), and the previous baseline predictors; considering 2-year variables, time to first relapse (2-year: β = -0.12, p = 0.01) entered, whereas high-efficacy treatment exposure exited the model. Predictors of 9-year disability worsening were: at baseline, presence of optic nerve lesions (odds ratio [OR] = 6.45, p = 0.01); considering 1-year and 2-year variables, Expanded Disability Status Scale (EDSS) changes (1-year: OR = 26.05, p < 0.001; 2-year: OR = 16.38, p = 0.02), and ≥ 2 new T2-lesions in 2 years (2-year: OR = 4.91, p = 0.02). Predictors of higher 9-year EDSS score were: at baseline, EDSS score (β = 0.58, p < 0.001), presence of brainstem lesions (β = 0.31, p = 0.04), and number of cervical cord lesions (β = 0.22, p = 0.05); considering 1-year and 2-year variables, EDSS changes (1-year: β = 0.79, p < 0.001; 2-year: β = 0.55, p < 0.001), and ≥ 2 new T2-lesions (1-year: β = 0.28, p = 0.03; 2-year: β = 0.35, p = 0.01). INTERPRETATION: A complete baseline MRI assessment and an accurate clinical and MRI monitoring during the first 2 years of disease contribute to predict 9-year prognosis in pediatric patients with multiple sclerosis. ANN NEUROL 2021;89:1011-1022.
引用
- De Meo E, Bonacchi R, Moiola L, et al. Early Predictors of 9-Year Disability in Pediatric Multiple Sclerosis. Ann Neurol. 2021. PMID: 33598931. doi:10.1002/ana.26052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。